EQ-5D BASED UTILITY VALUES BY CLINICAL RESPONSE AND SYMPTOM SEVERITY IN JAPANESE PATIENTS WITH MAJOR DEPRESSIVE DISORDER: POST-HOC ANALYSIS OF JAPANESE BREXPIPRAZOLE CLINICAL TRIALS
Author(s)
Yilong Zhang, MD1, Kentaro Yamato, PhD2, Tomohiro Kondo, MSc3, Koichi Kaya, bachelor3.
1HEOR/RWE, Otsuka Phamaceutical Co.,Ltd., Tokyo, Japan, 2Otsuka Holdings Co., Ltd., Tokyo, Japan, 3Otsuka Phamaceutical Co.,Ltd., tokyo, Japan.
1HEOR/RWE, Otsuka Phamaceutical Co.,Ltd., Tokyo, Japan, 2Otsuka Holdings Co., Ltd., Tokyo, Japan, 3Otsuka Phamaceutical Co.,Ltd., tokyo, Japan.
OBJECTIVES: Major depressive disorder (MDD) is a leading global cause of disability and substantially impairs quality of life and function. In Japan, the burden of MDD is considerable, yet utility values stratified by clinically defined symptom severity remain unclear. This study aimed to estimate utility values in Japanese patients with MDD according to both clinical response categories and symptom-severity levels, providing Japan-specific inputs for health economic evaluations.
METHODS: This post-hoc analysis used patient-level data from two Japanese brexpiprazole clinical trials (NCT03737474 and NCT03697603). The Montgomery-Åsberg Depression Rating Scale (MADRS) was used to define clinical response categories: remission (≥50% reduction and score ≤10), response (≥30% reduction), and no response (<30% reduction). Symptom severity was characterized using standard cut-offs for both MADRS (none: 0-6; mild: 7-19; moderate: 20-34; severe: ≥35) and the Hamilton Depression Rating Scale (HAM-D; none: 0-7; mild: 8-16; moderate: 17-23; severe: ≥24). Multilevel linear regression adjusted for age and sex estimated utilities, and correlations between depression symptom scores (MADRS and HAM-D) and EQ-5D-5L based utility were assessed using Spearman coefficients.
RESULTS: A total of 216 patients were included. Utilities were 0.7081 for no response, 0.7578 for response, and 0.8483 for remission states defined by MADRS clinical response. For symptom severity defined by MADRS, the utility values were 0.9151 for none, 0.8067 for mild, 0.7340 for moderate, and 0.6346 for severe. For symptom severity defined by HAM-D, the corresponding utility values were 0.8809 for none, 0.7925 for mild, 0.7376 for moderate, and 0.6449 for severe. MADRS and HAM-D scores were moderately and negatively correlated with utility (−0.5647 and −0.5651, respectively).
CONCLUSIONS: Utility values in Japanese MDD patients vary systematically with both symptom severity and MADRS-defined clinical response. These severity-based estimates provide robust inputs for Japan-specific health economic evaluations of MDD treatments.
METHODS: This post-hoc analysis used patient-level data from two Japanese brexpiprazole clinical trials (NCT03737474 and NCT03697603). The Montgomery-Åsberg Depression Rating Scale (MADRS) was used to define clinical response categories: remission (≥50% reduction and score ≤10), response (≥30% reduction), and no response (<30% reduction). Symptom severity was characterized using standard cut-offs for both MADRS (none: 0-6; mild: 7-19; moderate: 20-34; severe: ≥35) and the Hamilton Depression Rating Scale (HAM-D; none: 0-7; mild: 8-16; moderate: 17-23; severe: ≥24). Multilevel linear regression adjusted for age and sex estimated utilities, and correlations between depression symptom scores (MADRS and HAM-D) and EQ-5D-5L based utility were assessed using Spearman coefficients.
RESULTS: A total of 216 patients were included. Utilities were 0.7081 for no response, 0.7578 for response, and 0.8483 for remission states defined by MADRS clinical response. For symptom severity defined by MADRS, the utility values were 0.9151 for none, 0.8067 for mild, 0.7340 for moderate, and 0.6346 for severe. For symptom severity defined by HAM-D, the corresponding utility values were 0.8809 for none, 0.7925 for mild, 0.7376 for moderate, and 0.6449 for severe. MADRS and HAM-D scores were moderately and negatively correlated with utility (−0.5647 and −0.5651, respectively).
CONCLUSIONS: Utility values in Japanese MDD patients vary systematically with both symptom severity and MADRS-defined clinical response. These severity-based estimates provide robust inputs for Japan-specific health economic evaluations of MDD treatments.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
PCR8
Topic
Patient-Centered Research
Topic Subcategory
Health State Utilities, Patient-reported Outcomes & Quality of Life Outcomes